Status:
UNKNOWN
Intravenous Colistin Versus Intravenous Colistin Plus Nebulized Colistin in VAP Due MDR Acinetobacter Baumannii
Lead Sponsor:
Hospitales Universitarios Virgen del Rocío
Conditions:
Cross Infection
Pneumonia, Bacterial
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Compare the clinical efficiency evaluated by the treatment of the intravenous colistin plus inhaled colistin opposite to the treatment with colistin intravenous plus inhaled saline solution in patient...
Detailed Description
Compare the clinical efficiency evaluated by the treatment of the intravenous colistin plus inhaled colistin opposite to the treatment with colistin intravenous plus inhaled saline solution in patient...
Eligibility Criteria
Inclusion
- Diagnose of VAP due A. baumannii or A. baumannii and another microorganism carbapenems resistant.
- Clinical Pulmonary Infection Score (CPIS) \> 6
Exclusion
- Allergy to colistin.
- Asthma
- Shock status
- Diagnose of VAP due A. baumannii colistin resistant.
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2011
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT00645723
Start Date
April 1 2008
End Date
April 1 2011
Last Update
August 6 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitario Virgen del Rocío
Seville, Seville, Spain, 41008